CUFinder

Dr Michel Obeid MD PhD

About Dr Michel Obeid MD PhD

Dr Michel Obeid MD PhD, With an exceptional h-index of 24 and a recent h-index of 23 (since 2020), a distinguished researcher at Université de Lausanne, specializes in the field of Immuno-oncology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series

Novel targets for immune-checkpoint inhibition in cancer

A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells

Neoadjuvant immunotherapy: A promising new standard of care

Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies

Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis …

Dr Michel Obeid MD PhD Information

University

Position

CHUV

Citations(all)

11891

Citations(since 2020)

6246

Cited By

7740

hIndex(all)

24

hIndex(since 2020)

23

i10Index(all)

29

i10Index(since 2020)

27

Email

University Profile Page

Google Scholar

Dr Michel Obeid MD PhD Skills & Research Interests

Immuno-oncology

Top articles of Dr Michel Obeid MD PhD

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

Nature Communications

2024/4/30

Giuseppe Pantaleo
Giuseppe Pantaleo

H-Index: 11

Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series

2024/4

Fabio Becce
Fabio Becce

H-Index: 23

Novel targets for immune-checkpoint inhibition in cancer

2023/8/12

A CD64/FcγRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells

Frontiers in Immunology

2023/8/9

Constantinos Petrovas
Constantinos Petrovas

H-Index: 22

Giuseppe Pantaleo
Giuseppe Pantaleo

H-Index: 11

Neoadjuvant immunotherapy: A promising new standard of care

2023/7/24

Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies

Journal for Immunotherapy of Cancer

2023

Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer

Journal of Cancer

2023

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis …

Haematologica

2023/1/1

Grégoire Stalder
Grégoire Stalder

H-Index: 4

Giuseppe Pantaleo
Giuseppe Pantaleo

H-Index: 11

Olivier Spertini
Olivier Spertini

H-Index: 15

A differential process mining analysis of COVID-19 management for cancer patients

Frontiers in Oncology

2022/12/7

Erica Tavazzi
Erica Tavazzi

H-Index: 3

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

Annals of Oncology

2022/12/1

Infection disséminée à Herpes simplex après talimogene laherparepvec (T-VEC) pour un carcinome épidermoïde chez un transplanté cardiaque

Annales de Dermatologie et de Vénéréologie-FMC

2022/11/1

Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients

JAMA oncology

2022/5/1

Didier Trono
Didier Trono

H-Index: 54

Giuseppe Pantaleo
Giuseppe Pantaleo

H-Index: 11

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events

Journal for immunotherapy of cancer

2022

68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis

Journal for immunotherapy of cancer

2021

Reactivation of IgA vasculitis after COVID-19 vaccination

The Lancet Rheumatology

2021/9/1

Giuseppe Pantaleo
Giuseppe Pantaleo

H-Index: 11

Original Research Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

EUROPEAN JOURNAL OF CANCER

2021/5/1

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy

European Journal of Cancer

2021/5/1

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in cancer patients: a multi-center study

2021/5/1

Xuemei Wang
Xuemei Wang

H-Index: 2

John A Thompson
John A Thompson

H-Index: 14

Personalized Cytokine-Directed therapy with tocilizumab for refractory immune checkpoint Inhibitor–Related cholangiohepatitis

Journal of Thoracic Oncology

2021/2/1

Julien Vaucher
Julien Vaucher

H-Index: 12

Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis

Annals of Oncology

2020/12/1

See List of Professors in Dr Michel Obeid MD PhD University(Université de Lausanne)